ES2075893T3 - Activacion in vivo especifica de sede de farmacos terapeuticos. - Google Patents

Activacion in vivo especifica de sede de farmacos terapeuticos.

Info

Publication number
ES2075893T3
ES2075893T3 ES90902934T ES90902934T ES2075893T3 ES 2075893 T3 ES2075893 T3 ES 2075893T3 ES 90902934 T ES90902934 T ES 90902934T ES 90902934 T ES90902934 T ES 90902934T ES 2075893 T3 ES2075893 T3 ES 2075893T3
Authority
ES
Spain
Prior art keywords
white
activator
prodrogue
tissue
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90902934T
Other languages
English (en)
Inventor
Reinhard Bredehorst
Chong-Ho Kim
Richard Mccabe
Nicholas Pomato
Carl-Wilhelm Vogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2075893(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2075893T3 publication Critical patent/ES2075893T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

UN METODO DE ACTIVACION EN-VIVO ESPECIFICA DEL EMPLAZAMIENTO DE UNA PRODROGA EN UN ANIMAL UTILIZANDO UN CONJUGADO DE MITAD DE BLANCO ACTIVADOR PARA LOCALIZAR UN ACTIVADOR EN UN EMPLAZAMIENTO PREDETERMINADO DE USO Y UN COMPUESTO PRODROGA QUE ES TRANSFORMADO EN UNA DROGA ACTIVA ANTE LA PRESENCIA DEL ACTIVADOR. EN UNA PUESTA EN PRACTICA PREFERIDA DE LA INVENCION, LA MITAD DE BLANCO, EL ACTIVADOR Y LA PRODROGA MUESTRAN POCA O NINGUNA INMUNOGENIACIDAD EN EL ANIMAL QUE ESTA SIENDO TRATADO. LA MITAD DE BLANCO ES RELATIVAMENTE MAS ESPECIFICA PARA ENLAZARSE AL TEJIDO DE BLANCO QUE A UN TEJIDO SIN BLANCO. EL ACTIVADOR NO SE ENCUENTRA O NO ESTA PRESENTE EN SOLO PEQUEÑAS CANTIDADES EN CIRCULACION O EN TEJIDOS SIN BLANCO, NO TIENE UN SUSTRATO PARA SU ACTIVIDAD EN CIRCULACION O EN TEJIDO SIN BLANCO, PUEDE SER ENLAZADO A LA MITAD DE BLANCO Y ES CAPAZ DE TRANSFORMAR LA PRODROGA EN UNA DROGA ACTIVA. LA PRODROGA ES SELECCIONADA POR SU CAPACIDAD DE EJERCER UNA ACTIVIDAD CITOXICA EN EL TEJIDO DE BLANCO DESPUESDE HABER SIDO TRANSFORMADA POR EL ACTIVADOR.
ES90902934T 1989-01-23 1990-01-23 Activacion in vivo especifica de sede de farmacos terapeuticos. Expired - Lifetime ES2075893T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30099989A 1989-01-23 1989-01-23

Publications (1)

Publication Number Publication Date
ES2075893T3 true ES2075893T3 (es) 1995-10-16

Family

ID=23161497

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90902934T Expired - Lifetime ES2075893T3 (es) 1989-01-23 1990-01-23 Activacion in vivo especifica de sede de farmacos terapeuticos.

Country Status (12)

Country Link
EP (1) EP0454783B1 (es)
JP (1) JP3273608B2 (es)
KR (1) KR0185967B1 (es)
AT (1) ATE123414T1 (es)
AU (1) AU648015B2 (es)
CA (1) CA2025899A1 (es)
DE (1) DE69019959T2 (es)
DK (1) DK0454783T3 (es)
ES (1) ES2075893T3 (es)
FI (1) FI97692C (es)
NO (1) NO912864L (es)
WO (1) WO1990007929A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US5474772A (en) * 1989-08-02 1995-12-12 Cobe Laboratories, Inc. Method of treatment with medical agents
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
WO1991008770A1 (en) * 1989-12-11 1991-06-27 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
WO1994001137A1 (en) * 1992-07-06 1994-01-20 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
RU2189251C2 (ru) * 1994-12-23 2002-09-20 Зенека Лимитед Химические соединения
HUP9900062A3 (en) 1995-08-16 1999-11-29 Zeneca Ltd Chemical compounds
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
PL229108B1 (pl) * 2014-08-22 2018-06-29 Celther Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wydzielania i oczyszczania estrów chityny (mono-, di‑podstawionych) oraz kopoliestrów chityny z mieszanin poreakcyjnych
EP3970752A1 (en) * 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067774A (en) * 1971-05-14 1978-01-10 Syva Company Compounds for enzyme amplification assay
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
LU85581A1 (fr) * 1984-10-10 1986-06-11 Smb Lab Ensembles d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
WO1989000050A1 (en) * 1987-07-02 1989-01-12 Akzo N.V. Antigen recognized by mca 16-88
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies

Also Published As

Publication number Publication date
DE69019959D1 (de) 1995-07-13
NO912864D0 (no) 1991-07-22
EP0454783A1 (en) 1991-11-06
WO1990007929A1 (en) 1990-07-26
ATE123414T1 (de) 1995-06-15
EP0454783B1 (en) 1995-06-07
KR910700072A (ko) 1991-03-13
AU648015B2 (en) 1994-04-14
EP0454783A4 (en) 1992-01-15
DK0454783T3 (da) 1995-10-16
AU5039790A (en) 1990-08-13
FI913511A0 (fi) 1991-07-22
JP3273608B2 (ja) 2002-04-08
KR0185967B1 (ko) 1999-05-01
FI97692B (fi) 1996-10-31
FI97692C (fi) 1997-02-10
CA2025899A1 (en) 1990-07-24
NO912864L (no) 1991-09-19
JPH04503068A (ja) 1992-06-04
DE69019959T2 (de) 1995-10-05

Similar Documents

Publication Publication Date Title
ES2075893T3 (es) Activacion in vivo especifica de sede de farmacos terapeuticos.
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
DE69836352D1 (de) Transdermales therapeutisches Pflaster mit Capsaicin und seinen Analogen
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
UA41989C2 (uk) Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри
BR9911161A (pt) Processos para o tratamento de um volume particular de tecido de planta ou animal, para produção de pelo menos um agente fotoativado em um volume particular de material, para o tratamento médico de um volume particular de tecido, e, aparelhos para o tratamento de um volume particular de tecido de planta ou animal e, para administração de um tratamento médico fotodinâmico.
BR9712599A (pt) Processos para o tratamento de um volume particular, de câncer e de um volume de tecido canceroso em tecido e para produzir pelo menos um agente molecular foto-ativo num volume particular de material e aparelhos para o tratamento de um volume particular de tecido de planta ou de animal e para a administração de um tratamento médico foto-dinâmico
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
BR9809117A (pt) Composição de gel retardado de liberação prolongada, processo de produzir a mesma, formulação farmacêutica,e , processos de tratamento de uma indicação , de uma doença, e de uma inflamação com uma composição de liberação prolongada
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE59902270D1 (de) Feuchtigkeitsaktivierbares therapeutisches system
US4618490A (en) Method of treatment of animal and human tissues damaged by burns and frank visible gangrene
ES2084057T3 (es) Bacterina para el tratamiento de enfermedades causadas por f. necrophorum y procedimiento para su produccion.
AR003979A1 (es) Administracion transdermica de vorozol.
ATE139119T1 (de) Modulierung der reaktion von adenylatcyclase
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ES2138053T3 (es) Formulacion insecticida solida.
DK338583A (da) Fremgangsmaade og medikament til reduktion af vaevslaesioner i et dyr
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.
Kozlov et al. The microcirculation of patients with arterial ischemia of the lower extremities during laser therapy
RU94003799A (ru) Способ лечения псороптозов животных
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
UA23921A (uk) Спосіб лікування шлунково-стравохідного рефлюксу
RU92000934A (ru) Световод для облучения биообъектов
SU1824731A1 (ru) Способ лечения гнойно-некротических заболеваний копыт у крупного рогатого скота

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 454783

Country of ref document: ES